🔗 Share this article

The first new treatments for gonorrhoea in many years are being described as a "significant breakthrough" in the effort against increasingly resistant strains of the bacteria, according to researchers.

An International Public Health Issue

Cases of gonorrhoea are escalating worldwide, with figures suggesting over 82 million infections per year. Especially elevated rates are reported in the African continent and countries within the WHO's Western Pacific region, which encompasses China and Mongolia to New Zealand. In England, cases have hit a all-time high, while figures across Europe in 2023 were triple the level compared to the rates from 2014.

“The clearance of novel therapies for gonorrhoea is an significant and necessary development in the context of increasing worldwide cases, increasing antimicrobial resistance and the highly restricted available drugs presently on offer.”

Health officials are deeply concerned about the rise in drug-resistant strains. The World Health Organization has classified it as a "critical concern". Ongoing monitoring revealed that resistance to key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Recent Treatment Options Gain Clearance

One new antibiotic, also known as Nuzolvence, was approved by the US FDA in December for treating gonorrhoea. This STI can lead to major issues, including infertility. Scientists hope that targeted use of this new drug will help delay the development of resistance.

Another new antibiotic, created by the pharmaceutical company GSK, was also approved in close succession. This drug, which is employed against urinary tract infections, was demonstrated in studies to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Novel Partnership

Zoliflodacin stemmed from a new, not-for-profit approach for medication research. The charitable organization GARDP collaborated with the pharmaceutical company its industry partner to bring it to fruition.

“This approval signifies a major breakthrough in the therapy of superbug gonorrhoea, which until now has been staying ahead of medical innovation.”

Research Study Outcomes and Global Access

As per results detailed in a prominent scientific publication, zoliflodacin cured the vast majority of uncomplicated infections. This establishes an equal footing with the existing first-line therapy, which uses a dual-drug approach. The trial enrolled nearly 1,000 patients from various regions including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its collaboration, GARDP has the authority to make available and distribute the drug in numerous low-income and middle-income countries.

Clinicians directly involved have voiced hope. The availability of a single-dose, oral treatment like this is described as a "critical tool" for public health efforts. This is viewed as essential to alleviate the strain of the illness for people and to stop the proliferation of highly drug-resistant gonorrhoea around the world.